Shizuya Yamashita Selected Research

Shizuya Yamashita Research Topics

Disease

41	Atherosclerosis 10/2020 - 01/2002
26	Cardiovascular Diseases (Cardiovascular Disease) 08/2022 - 05/2002
24	Hypertriglyceridemia 02/2022 - 01/2004
23	Dyslipidemias (Dyslipidemia) 09/2021 - 03/2005
22	Coronary Artery Disease (Coronary Atherosclerosis) 08/2022 - 01/2004
19	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 08/2022 - 01/2004
18	Hyperlipidemias (Hyperlipidemia) 11/2020 - 05/2002
15	Xanthomatosis (Xanthoma) 06/2022 - 08/2005
14	Coronary Disease (Coronary Heart Disease) 02/2021 - 04/2003
10	Type 2 Diabetes Mellitus (MODY) 11/2020 - 09/2008
8	Inborn Genetic Diseases (Disease, Hereditary) 05/2022 - 09/2002
8	Cholesteryl Ester Transfer Protein Deficiency 03/2019 - 07/2002
8	Insulin Resistance 11/2018 - 05/2003
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2017 - 12/2006
6	Hypertension (High Blood Pressure) 05/2022 - 01/2004
6	Tangier Disease 08/2021 - 08/2002
6	Obesity 02/2017 - 01/2005
5	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2013
5	Inflammation (Inflammations) 10/2019 - 01/2012
5	Hyperlipoproteinemia Type III (Broad Beta Disease) 02/2017 - 06/2003
5	Platelet Glycoprotein IV Deficiency 01/2012 - 05/2003
4	Myocardial Infarction 02/2022 - 01/2012
4	Fibrosis (Cirrhosis) 01/2022 - 01/2013
4	Hypercholesterolemia 05/2019 - 09/2010
4	Drug-Related Side Effects and Adverse Reactions 06/2018 - 01/2016
3	Fatty Liver 01/2022 - 02/2002
3	Sitosterolemia 08/2021 - 09/2010
3	Stroke (Strokes) 06/2020 - 01/2019
3	Chronic Renal Insufficiency 06/2020 - 09/2010
3	Body Weight (Weight, Body) 02/2018 - 01/2015
3	Hypothyroidism 02/2017 - 11/2009
3	Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial) 09/2013 - 09/2008
3	ST Elevation Myocardial Infarction 01/2012 - 05/2010
2	Diabetes Mellitus 12/2022 - 01/2004
2	Carotid Artery Diseases 06/2022 - 11/2005
2	Pancreatitis 11/2020 - 09/2013
2	Liver Diseases (Liver Disease) 01/2020 - 02/2011
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 01/2019
2	Metabolic Diseases (Metabolic Disease) 01/2020 - 05/2019
2	Heart Failure 10/2019 - 01/2013
2	Hypoxia (Hypoxemia) 10/2019 - 10/2002
2	Hyperglycemia 06/2018 - 05/2009
2	Coronary Stenosis (Coronary Artery Stenosis) 02/2017 - 09/2012
2	Hyperlipoproteinemia Type V 09/2013 - 01/2012

Drug/Important Bio-Agent (IBA)

34	oxidized low density lipoproteinIBA 06/2022 - 10/2002
29	Lipoproteins (Lipoprotein)IBA 08/2022 - 05/2003
27	LipidsIBA 08/2022 - 01/2002
25	LDL CholesterolIBA 06/2022 - 01/2002
24	CholesterolIBA 01/2022 - 01/2002
20	HDL CholesterolIBA 05/2022 - 07/2002
19	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2022 - 05/2002
17	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 02/2022 - 01/2018
17	Triglycerides (Triacylglycerol)IBA 01/2021 - 09/2005
16	LDL Lipoproteins (beta Lipoproteins)IBA 06/2022 - 01/2004
16	HDL LipoproteinsIBA 08/2021 - 08/2002
16	Apolipoprotein B-48IBA 02/2017 - 06/2003
10	Probucol (Lorelco)FDA Link 06/2022 - 11/2005
9	ChylomicronsIBA 02/2017 - 06/2007
8	ApolipoproteinsIBA 08/2022 - 02/2002
7	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2007
7	Cholesterol Ester Transfer ProteinsIBA 03/2019 - 07/2002
7	Proteins (Proteins, Gene)FDA Link 03/2019 - 01/2004
7	AdiponectinIBA 01/2015 - 03/2005
6	Ezetimibe (Zetia)FDA Link 01/2019 - 09/2010
6	LDL Receptors (LDL Receptor)IBA 06/2018 - 10/2002
6	Fenofibrate (CiL)FDA LinkGeneric 06/2018 - 06/2010
6	Chylomicron RemnantsIBA 02/2017 - 06/2007
5	Pharmaceutical PreparationsIBA 05/2022 - 11/2009
5	Apolipoproteins E (ApoE)IBA 01/2018 - 08/2003
4	AntioxidantsIBA 02/2021 - 12/2008
4	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2021 - 01/2018
4	Fibric Acids (Fibrates)IBA 01/2020 - 08/2003
4	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2008 - 08/2005
3	Lipoprotein(a)IBA 08/2022 - 09/2008
3	gamma-sitosterol (beta-sitosterol)IBA 08/2021 - 09/2010
3	ProgranulinsIBA 01/2020 - 10/2013
3	Adenosine Triphosphate (ATP)IBA 01/2019 - 08/2002
3	Insulin (Novolin)FDA Link 01/2019 - 01/2015
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2015 - 03/2005
3	Niacin (Nicotinic Acid)FDA LinkGeneric 05/2015 - 04/2012
3	Hypolipidemic Agents (Antihyperlipidemics)IBA 01/2012 - 05/2002
2	Phytosterols (Plant Sterols)IBA 08/2021 - 09/2010
2	evolocumabIBA 11/2020 - 01/2014
2	campesterolIBA 05/2020 - 09/2010
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2020 - 02/2017
2	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 02/2017
2	Complement System Proteins (Complement)IBA 01/2020 - 03/2019
2	Apolipoprotein C-IIIIBA 03/2019 - 03/2005
2	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2018 - 02/2017
2	Fatty Acids (Saturated Fatty Acids)IBA 02/2017 - 05/2003
2	DiglyceridesIBA 02/2017 - 04/2012
2	Bile Acids and Salts (Bile Acids)IBA 01/2016 - 09/2010
2	MK-0524IBA 05/2015 - 01/2015
2	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 09/2013 - 01/2012
2	Apolipoproteins B (ApoB)IBA 10/2012 - 09/2005
2	Biomarkers (Surrogate Marker)IBA 09/2012 - 07/2011

Therapy/Procedure

16	Therapeutics 02/2022 - 08/2010
5	Secondary Prevention 02/2021 - 05/2002
3	Drug Therapy (Chemotherapy) 01/2016 - 09/2010
2	Ligation 10/2019 - 01/2013